Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Study Number:A081105
IRB Number:669435
Trial Type:Oncology - Pulmonary
Trial Status:Open to Accrual
Date Posted:
Principal Investigator:Mei Tang, MD
Contact Name:Steven Schmitt
Phone:(443) 849-3592
Fax:(443) 849-3777

For more details on this study, please refer to the Clinicaltrials.gov website at the link below:


IMPORTANT Visitor Policy Changes

Recent Stories
In the Media